Alyeska Investment Group L.P. boosted its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 97.3% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 401,082 shares of the company's stock after buying an additional 197,808 shares during the period. Alyeska Investment Group L.P. owned approximately 0.51% of IDEXX Laboratories worth $211,146,000 at the end of the most recent quarter.
Other institutional investors have also bought and sold shares of the company. SHP Wealth Management acquired a new stake in shares of IDEXX Laboratories during the 4th quarter worth approximately $26,000. Virtus Advisers LLC bought a new stake in IDEXX Laboratories during the third quarter worth $26,000. J.Safra Asset Management Corp bought a new stake in IDEXX Laboratories during the second quarter worth $25,000. Elevation Wealth Partners LLC raised its position in IDEXX Laboratories by 188.2% in the 2nd quarter. Elevation Wealth Partners LLC now owns 49 shares of the company's stock valued at $26,000 after buying an additional 32 shares during the last quarter. Finally, Wormser Freres Gestion boosted its holdings in IDEXX Laboratories by 671.4% during the fourth quarter. Wormser Freres Gestion now owns 54 shares of the company's stock worth $37,000 after purchasing an additional 47 shares during the last quarter. Institutional investors own 87.84% of the company's stock.
IDEXX Laboratories Price Performance
Shares of NASDAQ IDXX opened at $554.99 on Friday. The firm has a market capitalization of $43.72 billion, a P/E ratio of 39.03, a P/E/G ratio of 2.96 and a beta of 1.54. The company has a quick ratio of 0.87, a current ratio of 1.17 and a debt-to-equity ratio of 0.19. The stock's 50-day simple moving average is $559.01 and its two-hundred day simple moving average is $573.80. IDEXX Laboratories, Inc. has a twelve month low of $518.55 and a twelve month high of $769.98.
IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last released its quarterly earnings results on Tuesday, August 4th. The company reported $4.27 earnings per share for the quarter, beating the consensus estimate of $3.94 by $0.33. IDEXX Laboratories had a return on equity of 71.96% and a net margin of 25.03%.The firm had revenue of $1.22 billion for the quarter, compared to analysts' expectations of $1.20 billion. During the same quarter last year, the firm posted $3.50 EPS. The company's revenue was up 9.7% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. As a group, equities analysts anticipate that IDEXX Laboratories, Inc. will post 14.81 EPS for the current fiscal year.
Analysts Set New Price Targets
Several research firms have recently issued reports on IDXX. UBS Group upped their target price on IDEXX Laboratories from $620.00 to $670.00 and gave the company a "neutral" rating in a report on Wednesday, August 5th. Citigroup increased their price target on shares of IDEXX Laboratories from $650.00 to $670.00 and gave the company a "neutral" rating in a research report on Wednesday, August 5th. Barclays reduced their price target on shares of IDEXX Laboratories from $800.00 to $710.00 and set an "overweight" rating for the company in a research report on Tuesday, August 11th. Wall Street Zen downgraded shares of IDEXX Laboratories from a "buy" rating to a "hold" rating in a research report on Sunday, July 12th. Finally, Weiss Ratings downgraded IDEXX Laboratories from a "hold (c+)" rating to a "hold (c)" rating in a research note on Thursday. Six analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat, IDEXX Laboratories presently has an average rating of "Moderate Buy" and an average target price of $747.00.
Check Out Our Latest Stock Report on IDEXX Laboratories
IDEXX Laboratories Profile
(
Free Report)
IDEXX Laboratories, Inc NASDAQ: IDXX is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.
IDEXX's product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider IDEXX Laboratories, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IDEXX Laboratories wasn't on the list.
While IDEXX Laboratories currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
